Retrospective comparison of outcomes in patients with recurrent or refractory ovarian cancer treated with pegylated liposomal doxorubicin at an academic medical center
Public Deposited- Last Modified
- February 26, 2019
- Creator
-
Shen, Eric
- Affiliation: Eshelman School of Pharmacy
- Abstract
- Pegylated liposomal doxorubicin, or PLD, is a widely used agent in treating recurrent and refractory ovarian cancer. The brand name drug, Doxil® was the first FDA-approved PLD product used in the United States. In 2012, Doxil® supply issues prompted the FDA to approve the emergency importation of Lipodox™, which then was not FDA-approved, as an alternative to Doxil®, despite little data existing comparing the equivalency of the two. UNC Medical Center (UNCMC) has treated patients using both products based on availability. Due to the nuanced nature of liposomal drug products and the limited data concerning the therapeutic equivalency of these two drugs, outcomes of ovarian cancer patients treated with Lipodox™ were compared to those treated with Doxil®. This retrospective comparison suggests that the Doxil® drug shortage did not result in differences in patient outcomes when Lipodox™ was used as a monotherapy for relapsed and refractory ovarian cancer.
- Date of publication
- autumn 2016
- Keyword
- DOI
- Resource type
- Rights statement
- In Copyright
- Note
- Funding: None
- Advisor
- Gardiner, Michelle
- Degree
- Doctor of Pharmacy
- Academic concentration
- Pharmacy
- Honors level
- Honors
- Degree granting institution
- University of North Carolina at Chapel Hill
- Graduation year
- 2017
- Language
- English
Relations
- Parents:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
2016-10-31 Doxil Lipodox manuscript for honors FINAL.pdf | 2019-05-17 | Public | Download |